SEC Comment Letter 0000000000-22-012399 to Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc.
Date: Nov. 15, 2022 · CIK: 0001840233 · Accession: 0000000000-22-012399
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268264
Letter
United States securities and exchange commission logo November 15, 2022 Rene Russo Chief Executive Officer Xilio Therapeutics, Inc. 828 Winter Street, Suite 300 Waltham, MA 02451 Re:Xilio Therapeutics, Inc. Registration Statement on Form S-3 Filed November 9, 2022 File No. 333-268264 Dear Rene Russo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Molly W. Fox, Esq.
Show Raw Text
United States securities and exchange commission logo
November 15, 2022
Rene Russo
Chief Executive Officer
Xilio Therapeutics, Inc.
828 Winter Street, Suite 300
Waltham, MA 02451
Re:Xilio Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 9, 2022
File No. 333-268264
Dear Rene Russo:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Molly W. Fox, Esq.